Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A DNA methylation fingerprint of 1628 human samples.

Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, Monk D, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C, Esteller M.

Genome Res. 2012 Feb;22(2):407-19. doi: 10.1101/gr.119867.110. Epub 2011 May 25.

2.

DBCAT: database of CpG islands and analytical tools for identifying comprehensive methylation profiles in cancer cells.

Kuo HC, Lin PY, Chung TC, Chao CM, Lai LC, Tsai MH, Chuang EY.

J Comput Biol. 2011 Aug;18(8):1013-7. doi: 10.1089/cmb.2010.0038. Epub 2011 Jan 8.

PMID:
21214365
3.

Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.

Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y.

Cancer Res. 2003 Jul 15;63(14):4174-80.

4.

CpG island hypermethylation-associated silencing of small nucleolar RNAs in human cancer.

Ferreira HJ, Heyn H, Moutinho C, Esteller M.

RNA Biol. 2012 Jun;9(6):881-90. doi: 10.4161/rna.19353. Epub 2012 May 23.

5.

Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.

Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM.

Genome Res. 2011 Jul;21(7):1028-41. doi: 10.1101/gr.119347.110.

6.

Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.

Karpinski P, Walter M, Szmida E, Ramsey D, Misiak B, Kozlowska J, Bebenek M, Grzebieniak Z, Blin N, Laczmanski L, Sasiadek MM.

Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):201-8. doi: 10.1158/1055-9965.EPI-12-0157. Epub 2012 Nov 21.

7.

Hypermethylation of CpG islands is more prevalent than hypomethylation across the entire genome in breast carcinogenesis.

Tan J, Gu Y, Zhang X, You S, Lu X, Chen S, Han X, Sun Y.

Clin Exp Med. 2013 Feb;13(1):1-9. doi: 10.1007/s10238-011-0173-2. Epub 2012 Jan 4.

PMID:
22212995
8.

DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter.

Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G.

Hum Mol Genet. 2011 Nov 15;20(22):4299-310. doi: 10.1093/hmg/ddr356. Epub 2011 Aug 11.

9.

Genome-wide DNA methylation profiling using Infinium® assay.

Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL.

Epigenomics. 2009 Oct;1(1):177-200. doi: 10.2217/epi.09.14.

10.

Silencing of bidirectional promoters by DNA methylation in tumorigenesis.

Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP.

Cancer Res. 2006 May 15;66(10):5077-84.

11.

Regulation of AURKC expression by CpG island methylation in human cancer cells.

Fujii S, Srivastava V, Hegde A, Kondo Y, Shen L, Hoshino K, Gonzalez Y, Wang J, Sasai K, Ma X, Katayama H, Estecio MR, Hamilton SR, Wistuba I, Issa JP, Sen S.

Tumour Biol. 2015 Sep;36(10):8147-58. doi: 10.1007/s13277-015-3553-5. Epub 2015 May 20.

PMID:
25990457
12.

Conserved role of intragenic DNA methylation in regulating alternative promoters.

Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K, Heine VM, Rowitch DH, Xing X, Fiore C, Schillebeeckx M, Jones SJ, Haussler D, Marra MA, Hirst M, Wang T, Costello JF.

Nature. 2010 Jul 8;466(7303):253-7. doi: 10.1038/nature09165.

13.

Nucleosomes correlate with in vivo progression pattern of de novo methylation of p16 CpG islands in human gastric carcinogenesis.

Lu ZM, Zhou J, Wang X, Guan Z, Bai H, Liu ZJ, Su N, Pan K, Ji J, Deng D.

PLoS One. 2012;7(4):e35928. doi: 10.1371/journal.pone.0035928. Epub 2012 Apr 25. Erratum in: PLoS One. 2012;7(8). doi:10.1371/annotation/eb15769c-aa54-4963-8a13-1dd7e8242319.

14.

Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.

Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lübbert M, Zhou JH, Benedict WF, Jones PA.

J Natl Cancer Inst. 2001 Oct 3;93(19):1465-72.

PMID:
11584062
15.
16.

Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines.

Guilleret I, Benhattar J.

Biochem Biophys Res Commun. 2004 Dec 17;325(3):1037-43.

PMID:
15541393
17.

Determining the effect of DNA methylation on gene expression in cancer cells.

Lee CJ, Evans J, Kim K, Chae H, Kim S.

Methods Mol Biol. 2014;1101:161-78. doi: 10.1007/978-1-62703-721-1_9.

PMID:
24233782
18.

Abnormal CpG island methylation occurs during in vitro differentiation of human embryonic stem cells.

Shen Y, Chow J, Wang Z, Fan G.

Hum Mol Genet. 2006 Sep 1;15(17):2623-35. Epub 2006 Jul 26.

PMID:
16870691
19.

DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis.

Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, Campan M, Laird PW.

Lab Invest. 2008 Feb;88(2):161-70. Epub 2007 Dec 24.

20.

Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation.

Rideout WM 3rd, Eversole-Cire P, Spruck CH 3rd, Hustad CM, Coetzee GA, Gonzales FA, Jones PA.

Mol Cell Biol. 1994 Sep;14(9):6143-52.

Supplemental Content

Support Center